Related Experiment Videos
Clinical management of the obese hypertensive patient
1Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA.
Insights
Obesity and hypertension are complex public health issues with intertwined mechanisms and inadequate treatments. Understanding these links is crucial for developing effective therapies for obesity-hypertension.
Area of Science:
- Cardiology
- Metabolic Disorders
- Public Health
Background:
- Obesity and hypertension represent a significant public health challenge with poorly understood pathophysiological links.
- The interplay between expanded plasma volume, cardiac workload, and neurohormonal factors in obesity-hypertension remains a critical area of investigation.
Purpose of the Study:
- To review the complex pathophysiological mechanisms underlying the co-occurrence of obesity and hypertension.
- To evaluate the current therapeutic strategies for obesity and its impact on hypertension management.
Main Methods:
- Review of existing literature on the pathophysiology of obesity and hypertension.
- Analysis of hemodynamic, metabolic, and comorbid factors contributing to obesity-hypertension.
- Assessment of current treatment modalities for obesity and hypertension.
Main Results:
- Obesity leads to cardiac volume overload and hypertrophy, exacerbated by hypertension-induced pressure overload.
- Numerous pressor, peptide, hormonal, and neural mechanisms contribute to the obesity-hypertension link.
- Current obesity treatments are often inadequate, with pharmacotherapy posing risks, while hypertension management is feasible despite obesity.
Conclusions:
- The intricate relationship between obesity and hypertension necessitates a comprehensive understanding for effective clinical management.
- Suboptimal obesity treatments complicate the management of coexistent hypertension.
- Despite challenges, established antihypertensive therapies can be safely employed in patients with obesity and comorbid conditions.
Abstract:
Despite years of investigation our fundamental and clinical knowledge of the major public health problem, obesity-hypertension, is relatively meager and certainly inadequate. We are at a loss to explain why the pathophysiological mechanisms of obesity and hypertension are so inextricably intertwined. Adding to this frustration is the inadequacy of the treatment for obesity. Hemodynamically, we recognize that the expanded plasma volume caused by obesity imparts a significant volume overload on the heart, thereby increasing cardiac output, while the hypertension compounds this ventricular stress by an associated pressure overload. Thus, the ventricle has an eccentric as well as a concentric adaptive hypertrophy. Associated with obesity is an increased burden of pressor (e.g., catecholamine, angiotensin II); peptide (e.g., endothelin, insulin, leptin, natriuretic); hormonal (e.g., growth, steroids, thyroid); and neural mechanisms. Further complicating these alterations are electrolytic, lipid, uric acid, and other metabolic factors. Both diseases (obesity and hypertension) are exacerbated by frequently encountered comorbid pathophysiological disorders including atherosclerosis, ventricular dysfunction, diabetes mellitus, hyperlipidemias, and sleep apnea. To add to these issues, therapy for obesity-hypertension is suboptimal. Behavioral modification (of overweight and obesity) is commonly characterized by recidivism, and pharmacotherapy of obesity is woefully inadequate; the present agents either raise arterial pressure or are fraught with adverse effects. Fortunately, there are no contraindications imparted by obesity that complicate the drug treatment of the associated hypertension. Each of the lifestyle modifications and seven classes of antihypertensive therapy that is discussed herein is done in light of the coexistent hypertension and comorbid diseases.